about £¾ Corporate Overview £¾ Who We Are
 
On the strength of its competitive power in the domestic ethical market, Choongwae has built efficient sales network and superior product pipelines in I.V solutions, anticancer, antibiotic, cardiovascular, gastrointestinal, nephrology, antianaemic and antipsychotic. Choongwae is also pioneering in the important new field of diabetes treatment medicine
Choongwae is trying hard to provide everything about health that includes medical equipments, various home care products and OTC products.
Thanks to its original new technologies, Choongwae has opened up overseas markets with its high-quality bulk pharmaceuticals and finished products. Ketoconazole and Itraconazole, the Choongwae¡¯s successful antifungal agents, acquired COS certification in Europe. They are highly acclaimed in prestigious markets of Europe and Japan.
Choongwae successfully developed the next generation antibiotics Imipenem in 2004. it is expected to substitute 20 billion won worth of imported antibiotics, and, along with antifungals and cephalosporins, it will be one of the core products in opening the era of 100 million dollar exportation.
Choongwae¡¯s global business is expanding not only to the export of bulk pharmaceuticals and finished products, but also to licensing-out of technical know- hows and patents.
Choogwae attributes high value of its brand to its high-quality products, superior technology and excellent service.
Development of technology through the Global R&D Network

Since the early 1990¡¯s, Choongwae has built up the R&D network with labs all over the world. To be ahead in the post-genome ear of the 21st century, Choongwae has secured new technology and compound, and developed competitive research capacity.
Choongwae is currently retaining cutting-edge pharmaceutical technologies such as Focused Library concerning the transcription factor phosphorylase, HTS, the screening technique for effective new chemical entities, chemogenomics, pharmacokinetics, and drug efficacy evaluation technique. Based on these technologies, Choongwae developed Q-roxin in 2001.
Also, Choongwae licensed out new chemical entities technologies for breast cancer and irritable bowel syndrome to the Japanese company Chugai. Moreover, Choongwae achieved excellent results in deducing new candidate compounds against cancer.
Choongwae has secured the formulation technology that improves the solubilization of insoluble substance, and the world¡¯s best synthetic technology concerning Arizole antifungal agent, ¥â-Lactam antibiotic, Cephamycin.
Choongwae succeeded in the world¡¯s second synthesis of the crude materials of Imipenem, the next generation antibiotics, and acquired COS certification in Europe for Itraconazole and other antifungal agents. Choongwae is one of the leading companies in the high value-added pharmaceutical drugs industry.
As a leading IV producer in the world, Choongwae is taking pride in its technology for environment-friendly Non-PVC films and bags, and fully automatic system of their production. Choongwae succeeded in development of Non-PVC film with its own technology, and now starts to produce IV solution containers. Choongwae is currently building its second factory with global standards of equipments for the production of IV solutions.

Choongwae¡¯s ceaseless investment and technical development are now returning as profit, and a source of its competitiveness.
Choongwae¡¯s competitiveness is the reason why many companies and research institutes want to be its partners.
For a global company, Choongwae thinks yesterday¡¯s competitors can be today¡¯s partners. It is Choongwae¡¯s confidence that it can be a win-win partner with anyone at anytime in any place.